Navigation Links
Neptune Technologies successfully completes $2.75 million private placement with 10% management participation

Proceeds to be used to support the achievement of several value-creating

developments and commercial milestones of Acasti Pharma

LAVAL, QC, Oct. 9 /PRNewswire-FirstCall/ - The Board of Directors of Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today announced that the Company successfully completed as of October 8, 2008, the private placement of units of convertible debentures for gross proceeds of $2,750,000.

The convertible debentures bear interest at the rate of 8% per year and mature three years from issuance. Upon maturity, the convertible debentures may be redeemed by Neptune in cash or converted, with a premium, into Neptune common shares. The proceeds from this financing will be invested by Neptune into Acasti Pharma in order to reach several value-creating development and commercial milestones within Acasti Pharma's over-the-counter, prescription medical food and prescription drug programs. The Board of Directors' decision to proceed with the private placement up to a maximum of $2,750,000 was influenced by its desire to provide for minimum dilution while allowing Acasti Pharma to reach critical milestones during the next two years, which is expected to create substantial value for all shareholders.

Each unit of the private placement is comprised of a $1,000 convertible debenture, 400 warrants to acquire shares of Neptune at $1.25 per share and 400 call options allowing the holder to acquire from Neptune an equal number of Acasti Pharma Class A shares, priced at $0.25 per share, in each case expiring on April 30, 2010.

During a period of two years from the date of issuance, the debentures may be converted into units, each comprised of one Neptune common share priced at $1.25 for the principal portion of the convertible debenture and at market price of Neptune common shares for the accrued interest and one-half warrant exercisable at market price. During the time period from June 1, 2009 until November 30, 2010, the debentures may also be converted into Acasti Pharma units, each comprised of one Acasti Pharma common share and of one call option on the common shares of Acasti Pharma owned by Neptune. The conversion ratio of the debenture into common shares and call options increases over time, from $0.25 to $1.00 for the common shares and $0.50 to $1.50 for the call options, in order to reflect the value creation achieved through the attainment of several development and commercial milestones.

In the event that all debentures are converted into Neptune shares, the conversion of the debentures will result in the issuance of a maximum of 2,200,000 common shares of Neptune and if all warrants are exercised, it will generate at least an additional amount of $2,750,000 and also result in the issuance of 2,200,000 common shares. All securities issued pursuant to this private placement may not be transferred for a period of four (4) months following the closing of the private placement.

In addition to third-party investors, insiders also subscribed for 10% of the private placement illustrating the strong commitment of management to the growth of Neptune and Acasti Pharma.

About Acasti Pharma

Acasti Pharma's product portfolio includes proprietary novel long-chain omega-3 phospholipids sourced from sustainable abundant marine biomass including Antarctic krill (Euphausia superba). Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and play, as such, an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits, and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on the research and development of treatments for chronic cardiovascular conditions.

About Neptune Technologies

Neptune researches and develops proprietary bioactive ingredients and products for nutraceutical and pharmaceutical applications and is carrying out clinical research to show the therapeutic benefits of its products in various medical indications. The Company patents and protects its innovations and is continuously expanding its intellectual property portfolio. Neptune has already obtained many regulatory approvals allowing commercialization of its products in various geographic markets and has filed for and is expecting additional approvals. Neptune continues to strongly support its strategic development plan to form partnerships with worldwide leaders in the nutraceutical industry. Neptune has entered into agreements with Nestle and Yoplait, worldwide leading food manufacturers, and paved its entrance into the global functional food market.

Neither NASDAQ nor TSX venture exchange accepts responsibility for the

adequacy or accuracy of this press release.

Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports filed with the Securities and Exchange Commission and the Canadian securities commissions.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
2. Neptune Technologies & Bioressources Inc. Reports First Quarter Results and Business Update
3. Neptune strengthens scientific operations with the appointment of a new Scientific Advisory Board
4. Neptune Technologies & Bioressources Inc. Secures Access to Nationwide Consumer Mass Market in the United States
5. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
6. Neptune Technologies receives GRAS notification in the United States
7. Neptune Technologies expands into medicinal markets in Asia Pacific
8. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
9. The Omega-3 Industry Leader, Croda Health Care, selects Neptune Technologies Ingredients for New Essentially Brand
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
(Date:10/13/2015)... ... 2015 , ... The Pistoia Alliance has appointed Dr Steve ... drive to increase the organization’s impact on the global innovation landscape in life ... its work in supporting pre-competitive collaboration in the life sciences sector. Steve brings ...
(Date:10/13/2015)... Applied BioMath ( ), a computational ... the drug invention process, announced that it will sponsor ... 20-22, 2015 in Boston , MA.  ... CEO of Applied BioMath, will present "QSP approaches enabling quantitative ... trials" on Wednesday October 21st 2015 at 12:30PM.  ...
(Date:10/13/2015)... ARRY ), Avanex Life Sciences ... ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ) ... (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ), ... --> Cooperative research and development efforts with the ... to advancements in the treatment of severe wounds.  Biotech ...
(Date:10/13/2015)... and SAN DIEGO , ... Mast Therapeutics, Inc. have agreed to collaborate in the ... poloxamer 188 NF, marketed by BASF under the Kolliphor ... a variety of pharmaceutical and biological applications, such as ... is the starting material for Mast,s lead product candidate. ...
Breaking Biology Technology:
(Date:10/2/2015)... 2015 ) ... the Law Using Biometrics" report to their ... the addition of the "Enforcing the Law ... --> Research and Markets ( ) ... the Law Using Biometrics" report to their ...
(Date:9/30/2015)... Sept. 30, 2015  The global glucose monitoring device and ... So says a new report on the industry from Kalorama ... dominate the market, followed by continuous glucose monitoring and sensor ... the market for these products in its latest report, ... , ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
Breaking Biology News(10 mins):